首页> 美国卫生研究院文献>Scientific Reports >Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
【2h】

Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression

机译:组合生物活性植物药通过表观遗传激活ERα表达重新激活他莫昔芬治疗ER阴性乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Conventional cancer prevention has primarily focused on single chemopreventive compounds that may not be sufficiently efficacious. We sought to investigate potential combinatorial effects of epigenetic bioactive botanicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) and sulforaphane (SFN) in broccoli sprouts (BSp) on neutralizing epigenetic aberrations in estrogen receptor-α (ERα) leading to enhanced anti-hormone therapeutic efficacy in ERα-negative breast cancer. Our results showed that this combinatorial treatment re-sensitized ERα-dependent cellular inhibitory responses to an estrogen antagonist, tamoxifen (TAM), via at least in part, epigenetic reactivation of ERα expression in ERα-negative breast cancer cells. Further in vivo studies revealed the combinatorial diets of GTPs and BSp significantly inhibited breast tumor growth in ERα-negative mouse xenografts, especially when combined with TAM treatment. This novel treatment regimen can lead to remodeling of the chromatin structure by histone modifications and recruitment changes of transcriptional factor complex in the ERα promoter thereby contributing to ERα reactivation and re-sensitized chemotherapeutic efficacy of anti-hormone therapy. Our studies indicate that combinatorial bioactive botanicals from GTPs and BSp are highly effective in inhibiting ERα-negative breast cancer due at least in part to epigenetic reactivation of ERα, which in turn increases TAM-dependent anti-estrogen chemosensitivity in vitro and in vivo.
机译:常规的癌症预防主要集中在可能不够有效的单一化学预防化合物上。我们试图研究表观遗传生物活性植物药(包括绿茶多酚(GTPs)中的表没食子儿茶素-3-没食子酸酯(EGCG)和西兰花芽(BSp)中的萝卜硫素(SFN)对中和雌激素受体-α(ERα)的表观遗传畸变的潜在组合作用。导致ERα阴性乳腺癌的抗激素治疗功效增强。我们的研究结果表明,这种联合治疗至少部分通过ERα阴性乳腺癌细胞中ERα表达的表观遗传激活,可以重新激活对雌激素拮抗剂他莫昔芬(TAM)的ERα依赖性细胞抑制反应。进一步的体内研究表明,GTP和BSp的联合饮食显着抑制了ERα阴性小鼠异种移植物中的乳腺肿瘤生长,尤其是与TAM治疗联合使用时。这种新颖的治疗方案可通过组蛋白修饰和ERα启动子中转录因子复合物的募集变化来导致染色质结构重塑,从而有助于ERα的活化和抗激素疗法的重新敏化化疗功效。我们的研究表明,来自GTP和BSp的组合生物活性植物药在抑制ERα阴性乳腺癌方面非常有效,这至少部分是由于ERα的表观遗传学激活,这反过来又增加了TAM依赖的体外和体内抗雌激素化学敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号